# Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects

> **NCT01144026** · PHASE1,PHASE2 · COMPLETED · sponsor: **Thymon, LLC** · enrollment: 15 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** TUTI-16 (0.2mg)
- **BIOLOGICAL:** TUTI-16 (1.0 mg)

## Key facts

- **NCT ID:** NCT01144026
- **Lead sponsor:** Thymon, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2013-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01144026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01144026, "Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01144026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*